Neos' ADHD Drug Won't Launch Until 2017 As FDA Requires Clinical-Commercial Bridging Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Complete response letter seeks assessment of food effect of Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets).
You may also be interested in...
Keeping Track: Cardio, Antibiotic Approvals Put FDA Over Last Year's Novel Drug Count
The latest drug development news and US FDA highlights from our Performance Tracker.
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
The latest drug development news and highlights from our FDA Performance Tracker.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.